Objectives: Enzyme-linked immunosorbent assay (ELISA) and Western blotting techniques were used to investigate and compare the expression of tissue plasminogen activator (tPA) in benign (meningioma) and malignant (glioblastoma) human brain tumours.
Methods: A total of 22 tumour samples comprising 11 meningiomas and 11 glioblastomas with adjacent peritumoural tissue were analysed.
Results: The mean tPA content of meningiomas was approximately half that of glioblastomas (55.40 (S.D. 34.58) versus 106.98 (S.D. 43.82) ng/ml, p=0.006). Comparing tPA quantity in tumour and peritumoural tissue, there was a significant difference for meningiomas (55.40 (S.D. 34.58) versus 28.35 (S.D. 22.55) ng/ml, p=0.05), but no difference for glioblastomas (106.98 (S.D. 43.82) versus 84.23 (S.D. 57.39) ng/ml, p=0.32). Comparing tumour with normal brain tissue, there was no difference for meningiomas (55.40 (S.D. 34.58) versus 33.08 (S.D. 21.55) ng/ml, p=0.22), but a significant difference for glioblastomas (106.98 (S.D. 43.82) versus 33.08 (S.D. 21.55) ng/ml, p=0.004). Western blotting showed that in the meningioma group, the molecular weight pattern was constant with a dominant well-defined band at 41kD. Peritumoural tissue demonstrated two bands, with the stronger band at 41kD and a slightly weaker band at 71kD. In the glioblastoma group, there was more heterogeneity, with a dominant 41kD band found in all tumour and peritumoural samples, together with additional bands at 34, 58 and 66kD.
Conclusion: These results indicate that (1) tPA is present in larger quantities in glioblastoma compared to meningioma and normal brain, (2) tPA quantity is not significantly different in the peritumoural tissue adjacent to glioblastoma but is significantly less for meningioma, and (3) tPA is expressed in more heterogenous forms in glioblastoma. This present study therefore suggests that the expression of tPA in a brain tumour may be an additional prognostic factor in terms of its malignant and invasive potential.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clineuro.2004.09.010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Post-operative glioblastoma cancer cell distribution in the peritumoural oedema.
Front Oncol
December 2024
Division of Mathematics, University of Dundee, Dundee, United Kingdom.
Glioblastoma multiforme (GBM), the most aggressive primary brain tumour, exhibits low survival rates due to its rapid growth, infiltrates surrounding brain tissue, and is highly resistant to treatment. One major challenge is oedema infiltration, a fluid build-up that provides a path for cancer cells to invade other areas. MRI resolution is insufficient to detect these infiltrating cells, leading to relapses despite chemotherapy and radiotherapy.
View Article and Find Full Text PDFAtezolizumab, bevacizumab, pemetrexed and platinum for EGFR-mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis.
Clin Transl Med
January 2025
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Background: Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) remains a significant hurdle for patients with EGFR-mutated non-small cell lung cancer (NSCLC), particularly those lacking the EGFR. IMpower 150 study demonstrated promising efficacy for a combination of immune-chemotherapy and bevacizumab in patients with EGFR-mutated NSCLC.
Methods: This open-label, single-arm, phase II trial evaluated the efficacy and immune cell profile of the modified regimen combining atezolizumab, bevacizumab (7.
CXCL12-targeted immunomodulatory gene therapy reduces radiation-induced fibrosis in healthy tissues.
Mol Cancer Ther
December 2024
Institute of Cancer Research, London, United Kingdom.
Radiation-induced fibrosis (RIF) is a progressive pathology deleteriously impacting cancer survivorship. CXCL12 is an immune-stromal signal implicated in fibrosis and innate response. We hypothesised that modulation of CXCL12 would phenotypically mitigate RIF.
View Article and Find Full Text PDFRadiomic Gradient in Peritumoural Tissue of Liver Metastases: A Biomarker for Clinical Practice? Analysing Density, Entropy, and Uniformity Variations with Distance from the Tumour.
Diagnostics (Basel)
July 2024
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy.
The radiomic analysis of the tissue surrounding colorectal liver metastases (CRLM) enhances the prediction accuracy of pathology data and survival. We explored the variation of the textural features in the peritumoural tissue as the distance from CRLM increases. We considered patients with hypodense CRLMs >10 mm and high-quality computed tomography (CT).
View Article and Find Full Text PDFImproved tumour delivery of iron oxide nanoparticles for magnetic hyperthermia therapy of melanoma ultrasound guidance and In SPECT quantification.
Nanoscale
October 2024
Healthcare Biomagnetics Laboratory, University College London, 21 Albemarle Street, London, W1S 4BS, UK.
Magnetic field hyperthermia relies on the intra-tumoural delivery of magnetic nanoparticles by interstitial injection, followed by their heating on exposure to a remotely-applied alternating magnetic field (AMF). This offers a potential sole or adjuvant route to treating drug-resistant tumours for which no alternatives are currently available. However, two challenges in nanoparticle delivery currently hinder the effective clinical translation of this technology: obtaining enough magnetic material within the tumour to enable sufficient heating; and doing this accurately to limit or avoid damage to surrounding healthy tissue.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!